The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv, And More

An Oncorus Inc (ONCR) director indirectly scooped up 300,000 of its shares last week. At a secondary offering price of $19.00, that cost him $5.70 million, and it raised the stake to more than 1.40 million shares. Unfortunately for that director, the stock ended the week trading at $17.55 per share.

Corvus Pharmaceuticals Inc (CRVS) CEO Richard Miller and another director took advantage of a secondary offering. For $3.50 apiece, the almost 1.39 million shares acquired cost them about $4.85 million. Note that the other director also bought $30 million in Decibel Therapeutics shares (see above) at about the same time.

Neximmune Inc (NEXI) had its chief operating officer and three other insiders step up to the buy window during the week. The almost 241,800 shares they acquired altogether, at an IPO price of $17.00 per share, added up to around $3.81 million. The stock ended the week trading at $23.00 a share.

And Fiserv Inc (FISV) saw a director acquire 9,100 of its shares early in the week. At an average share price of $110.99, that cost the director about $1.10 million. This fintech company's stock ended Friday's trading at $111.36 per share, but it is still down over 2% since the beginning of the year.

Note that some smaller amount of insider buying at Black Knight Inc (BKI), BridgeBio Pharma Inc (BBIO), CVS Health Corp (CVS), Northwest Bancshares, Inc. (NWBI), Nu Skin Enterprises, Inc. (NUS), SLM Corp (SLM), and United States Steel Corporation (X) was reported in the past week, as well.

1 2
View single page >> |

Disclaimer: At the time of this writing, the author had no position in the mentioned equities.

© 2021 Benzinga does not provide investment advice. All rights ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.